Eli Lilly and Co. is investing $1 billion to expand its Limerick, Ireland, manufacturing site to increase production of biologic active ingredients, including those for its recently approved treatment for early symptomatic Alzheimer’s disease. The company also invested in an $800 million facility expansion in Kinsale, Ireland, which began making medicines last year to meet demand for its latest diabetes and obesity treatments.   This additional investment is part of Lilly’s manufacturing...